Maxalt Melt

Rizatriptan, the active ingredient in Maxalt Melt, is a Triptan presented as an orally disintegrating tablet (melt) for oral use. It treats acute migraine attacks in adults, providing rapid relief of headache and associated symptoms. GNH USA supplies Maxalt Melt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rizatriptan is a triptan used for the acute treatment of migraine attacks.

Migraine (without aura): reduces headache intensity and associated nausea when taken at the onset of an attack. Migraine with aura: alleviates visual and sensory disturbances accompanying the headache phase. Acute migraine in adults: improves functional ability and allows patients to resume daily activities more quickly.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Taste disturbance or metallic taste - Mild nausea or stomach discomfort - Dizziness or light‑headedness - Fatigue or drowsiness - Dry mouth - Sensations of tingling or warmth

Serious or Rare Side Effects: - Chest pain or tightness indicating possible cardiac involvement - Serotonin syndrome, especially when combined with other serotonergic agents - Severe allergic reactions such as anaphylaxis or angioedema - Persistent visual disturbances or new neurological symptoms

Before using Maxalt Melt, consider the following safety measures. - Cardiovascular assessment: evaluate history of coronary artery disease or uncontrolled hypertension. - Contraindication review: avoid in patients with known hypersensitivity to rizatriptan or other triptans. - Drug interaction check: do not co‑administer with ergot alkaloids or other triptans. - Caution in hepatic impairment: dose adjustment may be required. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Rizatriptan can interact with several medication classes; monitoring is essential.

Major Interactions (Avoid): - Other triptans: combined use increases risk of vasospasm. - Ergot alkaloids: additive vasoconstrictive effects may lead to serious cardiovascular events. - Monoamine oxidase inhibitors (MAOIs): can precipitate severe hypertension. - SSRIs, SNRIs, or other serotonergic agents: may raise the risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: rizatriptan may enhance blood‑pressure‑lowering effects. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase plasma concentrations of rizatriptan, requiring dose adjustment.